Kaiku Health raises EUR4.4 million series A financing to accelerate its digital therapeutics pipeline led by Debiopharm and Tesi

Lausanne, Switzerland and Helsinki, Finland (ots) - Finnish
digital health company Kaiku Health Oy, which provides intelligent
patient monitoring software for healthcare providers across Europe,
has closed a EUR4.4 million funding round. The investment was led by
Debiopharm Innovation Fund SA and Tesi with participation from
Prodeko Ventures Oy and existing investors Reaktor Ventures Oy,
Metsola Ventures Oy, and Athensmed Oy.

Kaiku Health will use the funding to power its international
expansion and further develop its digital therapeutics pipeline.
Together with its partners, Kaiku Health will conduct several
clinical trials validating the digital therapeutics offering.

Kaiku Health offers intelligent patient monitoring software for
healthcare providers, mainly in oncology. Structured capture and
analysis of patient-reported data enables clinicians to evaluate the
effectiveness of therapies and to detect and treat health problems
early. Kaiku Health platform is used in routine care by over 30
clinics in Switzerland, Germany, Italy, Sweden, and Finland, and has
been used by 64,000 patients (March 2018).

"We have seen the significant positive impact our patient
monitoring platform can have on people's health", comments Lauri
Sippola, Kaiku Health CEO and Co-Founder. "This funding allows us to
provide our platform to a growing number of healthcare providers and
patients internationally. It is important that our investors also
bring an extraordinary understanding of healthcare, life sciences and
digitalization."

"We are excited about the impact digital technologies will have on
the patient journey and are particularly enthusiastic to help take
the digital therapeutic approach in oncology out of the lab and onto
the market where the benefits of this high frequency monitoring can
be expected to bring real outcomes improvement", says Tanja Dowe, CEO
at Debiopharm Innovation Fund.

"We have studied the Finnish digital health sector thoroughly and
found it extremely interesting from an investor's point of view",
adds Joni Karsikas, Investment Manager at Tesi. "The Kaiku Health
team impressed us with its strong technological know-how, for
instance in the use of artificial intelligence. Kaiku Health has
strong international customer references and a broad user-base for a
young health-tech company."

More information

Kaiku Health www.kaikuhealth.com @KaikuHealth

Debiopharm Innovation Fund www.debiopharm.com @DebiopharmNews

Tesi www.tesi.fi @TesiFII

Contact:
Kaiku Health Contact
Lauri Sippola, CEO & Co-Founder
lauri.sippola@kaikuhealth.com
Tel: +35840 744 7481

Debiopharm Group Contact
Christelle von Büren
Communication Coordinator
christelle.vonburen@debiopharm.com
Tel: +41 (0)21 321 01 11

Tesi Contact
Joni Karsikas, Investment Manager
joni.karsikas@tesi.fi
Tel: +358 40 827 0395

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell